[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SE8100104L - PHARMACEUTICAL COMPOSITIONS - Google Patents

PHARMACEUTICAL COMPOSITIONS

Info

Publication number
SE8100104L
SE8100104L SE8100104A SE8100104A SE8100104L SE 8100104 L SE8100104 L SE 8100104L SE 8100104 A SE8100104 A SE 8100104A SE 8100104 A SE8100104 A SE 8100104A SE 8100104 L SE8100104 L SE 8100104L
Authority
SE
Sweden
Prior art keywords
amount
milligrams
release controlling
agent
controlling agent
Prior art date
Application number
SE8100104A
Other languages
Unknown language ( )
Swedish (sv)
Other versions
SE447450B (en
Inventor
J M Dunn
J F Lampard
Original Assignee
Boots Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/194,453 external-priority patent/US4308251A/en
Application filed by Boots Co Ltd filed Critical Boots Co Ltd
Publication of SE8100104L publication Critical patent/SE8100104L/en
Publication of SE447450B publication Critical patent/SE447450B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A sustained release pharmaceutical composition in table-t form comprises an effective amount of an orallyactive therapeutic agent, 0.8 to 1. 6% by weight of a release controlling agent and 1.0 to 7.5% by weight of an erosion promoting agent, the relative amounts of the components being such that a criticality factor calculated according to equation I lies in the range 20 to 450. Equation 1 is <IMG> I wherein CF is the criticality factor, CA is the. amount of therapeutic agent per tablet in milligrams divided by the amount of release controlling agent per tablet in milligrams and CS is the amount of erosion promoting agent per tablet in milligrams divided by the amount of release controlling agent per-tablet in milligrams, Suitable therapeutic agents include acetylsalicylic acid, ibuprofen and flurbiprofen. A preferred release controlling agent is cellulose acetate phthalate and a preferred erosion promoting agent is corn starch.
SE8100104A 1980-01-11 1981-01-09 PHARMACEUTICAL COMPOSITIONS WITH CONTINUOUS TABLE PREPARATION AND WAY TO PREPARE THESE SE447450B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11143080A 1980-01-11 1980-01-11
US06/194,453 US4308251A (en) 1980-01-11 1980-10-17 Controlled release formulations of orally-active medicaments

Publications (2)

Publication Number Publication Date
SE8100104L true SE8100104L (en) 1981-07-12
SE447450B SE447450B (en) 1986-11-17

Family

ID=26808896

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8100104A SE447450B (en) 1980-01-11 1981-01-09 PHARMACEUTICAL COMPOSITIONS WITH CONTINUOUS TABLE PREPARATION AND WAY TO PREPARE THESE

Country Status (22)

Country Link
JP (1) JPS56103110A (en)
AT (1) AT374681B (en)
AU (1) AU542824B2 (en)
BE (1) BE886998A (en)
CA (1) CA1140466A (en)
CH (1) CH646604A5 (en)
DE (1) DE3100191A1 (en)
DK (1) DK6181A (en)
ES (2) ES498369A0 (en)
FI (1) FI76927C (en)
FR (1) FR2473308B1 (en)
GB (1) GB2067072B (en)
GR (1) GR73843B (en)
IE (1) IE50806B1 (en)
IN (1) IN151913B (en)
IT (1) IT1221041B (en)
LU (1) LU83052A1 (en)
NL (1) NL8100037A (en)
NO (1) NO156153C (en)
NZ (1) NZ195933A (en)
SE (1) SE447450B (en)
ZA (1) ZA81136B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2496082A (en) * 1947-05-24 1950-01-31 Ashenfelter William Scaffold structure
IT1144911B (en) * 1981-03-19 1986-10-29 Pharmatec Spa CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING IBUPROFEN
JPS59227817A (en) * 1983-06-07 1984-12-21 Toyo Jozo Co Ltd Long-acting bredinin preparation for oral administration
JPH0662404B2 (en) * 1983-06-14 1994-08-17 シンテックス・ファーマシユーテイカルズ・インターナシヨナル・リミテツド Controlled-release naproxen and naproxen sodium tablets
ZA836031B (en) * 1983-08-16 1985-02-27 Verex Lab Constant release rate solid dosage theophylline formulation
ZA836030B (en) * 1983-08-16 1985-02-27 Verex Lab Constant order release solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
EP0138216B1 (en) * 1983-10-14 1993-01-07 Sumitomo Pharmaceuticals Company, Limited Sustained-release ifn preparation for parenteral administration
US5385738A (en) * 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
US4855134A (en) * 1983-10-14 1989-08-08 Sumitomo Pharmaceuticals Company, Limited Sustained-release preparation
CA1277601C (en) * 1985-12-27 1990-12-11 Shigeji Sato Method for producing sustained release formulation
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
ZA881301B (en) * 1987-02-27 1989-10-25 Lilly Co Eli Sustained release matrix formulations
US5855915A (en) * 1995-06-30 1999-01-05 Baylor University Tablets or biologically acceptable implants for long-term antiinflammatory drug release

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953497A (en) * 1953-06-03 1960-09-20 Howard A Press Therapeutic tablets
BE604564A (en) * 1960-06-06
US3577514A (en) * 1968-06-10 1971-05-04 Pfizer Sustained release pharmaceutical tablets
US3773920A (en) * 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
US3906086A (en) * 1971-07-19 1975-09-16 Richard G Powers Timed-release aspirin
GB1500300A (en) * 1975-01-06 1978-02-08 Ciba Geigy Ag Pharmaceutical preparation for the treatment of circulatory disorders
JPS5411226A (en) * 1977-06-24 1979-01-27 Shin Etsu Chem Co Ltd Disintegratable granule

Also Published As

Publication number Publication date
ES8205353A1 (en) 1982-06-01
JPS56103110A (en) 1981-08-18
ES498369A0 (en) 1982-06-01
NO156153C (en) 1987-08-05
CA1140466A (en) 1983-02-01
ZA81136B (en) 1982-01-27
FI810056L (en) 1981-07-12
DE3100191A1 (en) 1981-12-10
ES509179A0 (en) 1982-12-16
LU83052A1 (en) 1982-09-10
ATA5481A (en) 1983-10-15
SE447450B (en) 1986-11-17
FI76927B (en) 1988-09-30
IE50806B1 (en) 1986-07-23
NO810062L (en) 1981-07-13
BE886998A (en) 1981-07-08
ES8301629A1 (en) 1982-12-16
AU542824B2 (en) 1985-03-14
FR2473308B1 (en) 1985-07-19
FR2473308A1 (en) 1981-07-17
IN151913B (en) 1983-09-03
CH646604A5 (en) 1984-12-14
NZ195933A (en) 1982-11-23
AT374681B (en) 1984-05-25
DE3100191C2 (en) 1988-09-01
IE810036L (en) 1981-07-11
GB2067072B (en) 1983-08-10
NO156153B (en) 1987-04-27
NL8100037A (en) 1981-08-03
GB2067072A (en) 1981-07-22
DK6181A (en) 1981-07-12
GR73843B (en) 1984-05-07
FI76927C (en) 1989-01-10
IT8147537A0 (en) 1981-01-09
AU6597681A (en) 1981-07-16
IT1221041B (en) 1990-06-21

Similar Documents

Publication Publication Date Title
SE8100104L (en) PHARMACEUTICAL COMPOSITIONS
IT1180193B (en) SOLID PHARMACEUTICAL FORMULATIONS INTENDED TO BE SLOWLY FREE, OF ZERO ORDER, THROUGH CONTROLLED SURFACE EROSION OF LARGE CAPACITY
GT198303076A (en) FORMULATIONS OF PROLONGED ACTION TABLETS WITH PAULATINE DISSOLUTION.
ATE61050T1 (en) PYRIDAZINAMINES EFFECTIVE AGAINST VIRUSES.
LV5801A4 (en) Omeprazole added to the basal islet
IE791172L (en) Pharmaceutical compositions containing urea
ES8502334A1 (en) Elastase-containing composition permitting elastase to be absorbed in increased amount.
ES460098A1 (en) Derivatives of penicillanic acid
ES465906A1 (en) Prolonged-release pharmaceutical compositions for oral administration, their methods of making and use
GB1353635A (en) Coating composition for moist surfaces
NO891220D0 (en) COMPOSITION CONTAINING SALICYLIC ACID FOR TREATING LEPIDOSE.
ES433860A1 (en) 3-(4{40 -Alkoxy-benzoyl)-1,2,2-trimethylcyclopentane-carboxylic acids, methods of use and compositions containing such compounds
FR2413909A1 (en) THERAPEUTIC COMPOSITIONS BASED ON 1- (2-CHLORODIBENZO (B, F) OXEPINE-10-YL) -4-METHYLPIPERAZINE
US3035987A (en) Method of increasing the water vapor porosity of fat materials
ATE37185T1 (en) CONTRACEPTIVE COMPOSITIONS BASED ON LEVO-NORGESTREL ESTERS.
ES8304992A1 (en) Bis-esters of alkanediols, pharmaceutical compositions thereof and intermediates therefor.
GB1381426A (en) Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents
ES466493A1 (en) 4-phenylbutyric acid dervatives process for their preparation and pharmaceutical compostions containing them
GB1527781A (en) Anti-inflammatory composition
ATE16100T1 (en) ESTERS OF 1-METHYL-5-P-TOLUOYLPYRROLYL-2ACETIC ACID WITH ANTI-INFLAMMATORY, MUCOLYTIC AND ANTI-TUSSIVE PROPERTIES, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
GB1261989A (en) 5-thiazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing the same
DE69213113D1 (en) Solid, stabilized pharmaceutical form of compositions containing choline metal carboxymethyl cellulose salicylate
LU81501A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING TRIMETHOPRIME, AS WELL AS N-ETHYL-GAMMA-PYRIDONE-3-CARBOXYLIC ACID DERIVATIVES
JPS56122312A (en) Hepatic cholesterol-lowering agent (hepatic decholesterolizing agent)
GB1253786A (en) Therapeutic compositions

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8100104-2

Effective date: 19901211

Format of ref document f/p: F